Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein.
DrugDrug NameDrug Indication
DB00001LepirudinFor the treatment of heparin-induced thrombocytopenia
DB00002CetuximabCetuximab, used in combination with irinotecan, is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are refractory to irinotecan-based chemotherapy. Cetuximab administered as a single agent is indicated for the treatment of EGFR-expressing, metastatic colorectal carcinoma in patients who are intolerant to irinotecan-based chemotherapy.
DB00003Dornase alfaUsed as adjunct therapy in the treatment of cystic fibrosis.
DB00004Denileukin diftitoxFor treatment of cutaneous T-cell lymphoma
DB00005EtanerceptEtanercept is indicated for the treatment of moderately to severely active rheumatoid arthritis in adults and chronic moderate to severe plaque psoriasis in adults. It is also used to manage signs and symptoms of polyarticular idiopathic arthritis in those aged 4 to 17 after insufficient response to one or more disease-modifying anti-rheumatic drugs. Etanercept is also used to improve psoriatic arthritis and ankylosing spondylitis.
DB00006BivalirudinFor treatment of heparin-induced thrombocytopenia and for the prevention of thrombosis. Bivalirudin is indicated for use in patients undergoing percutaneous coronary intervention (PCI), in patients at moderate to high risk acute coronary syndromes due to unstable angina or non-ST segment elevation in whom a PCI is planned.
DB00007LeuprolideFor treatment of prostate cancer, endometriosis, uterine fibroids and premature puberty
DB00008Peginterferon alfa-2aPeginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies. Peginterferon alfa-2a is also indicated as a monotherapy for adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation [FDA Label].
DB00009AlteplaseFor management of acute myocardial infarction, acute ischemic strok and for lysis of acute pulmonary emboli
DB00010SermorelinFor the treatment of dwarfism, prevention of HIV-induced weight loss
DB00011Interferon alfa-n1For treatment of venereal or genital warts caused by the Human Papiloma Virus
DB00012Darbepoetin alfaFor the treatment of anemia (from renal transplants or certain HIV treatment)
DB00013UrokinaseUrokinase can be used for the treatment of pulminary embolism, coronary artery thrombosis, IV catheter clearance, and venous and arterial blood clots.
DB00014GoserelinUsed to treat hormone-sensitive cancers of the breast (in pre- and peri- menopausal women) and prostate, and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty.
DB00015ReteplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00016ErythropoietinIndicated in adult and paediatric patients for the: - treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis. - treatment of anemia due to zidovudine in patients with HIV-infection. - treatment of anemia due to the effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy. - reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery.
DB00017Salmon CalcitoninUsed in the treatment of symptomatic Paget's disease for patients unresponsive to alternate treatments or intolerant to such treatments. In addition, it is used in emergency situations when serum calcium levels must be decreased quickly until the underlying condition is identified. It can also be added to existing therapeutic regimens for hypercalcemia such as intravenous fluids and furosemide, oral phosphate or corticosteroids, or other agents. Calcitonin can be used in patients with azotemia and cases where intravenous fluids would be contraindicated due to limited cardiac reserves. Also for the treatment of post-menopausal osteoporosis in women more than 5 years post-menopause.
DB00018Interferon alfa-n3For the intralesional treatment of refractory or recurring external condylomata acuminata.
DB00019PegfilgrastimPegfilgrastim is indicated for use in patients receiving myelosuppressive chemotherapy for non-myeloid malignancies to reduce the incidence of infection.
DB00020SargramostimFor the treatment of cancer and bone marrow transplant
DB00021SecretinFor diagnosis of pancreatic exocrine dysfunction and gastrinoma
DB00022Peginterferon alfa-2bPeginterferon alfa-2b is indicated for the treatment of HCV in combination with [DB00811] and a NS3/4A protease inhibitor for genotype 1 or without a NS3/4A protease inhibitor for genotypes 2-6 [FDA Label]. May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
DB00025Antihemophilic factor, human recombinantFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
DB00026AnakinraFor the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
DB00027Gramicidin DFor treatment of skin lesions, surface wounds and eye infections.
DB00028Immune Globulin HumanIVIg is used in the treatment of immunodeficiencies, as well as autoimmune and inflammatory disorders. These indications includes idiopathic thrombocytopenic purpura, Kawasaki disease, hypogammaglobulinemia, B cell chronic lymphocytic leukemia, bone marrow transplant complications, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), multiple sclerosis, rheumatoid arthritis, myesthenia gravis, Wiskott–Aldrich syndrome and inflammatory skin diseases.
DB00029AnistreplaseFor lysis of acute pulmonary emboli, intracoronary emboli and management of myocardial infarction
DB00031TenecteplaseFor treatment of myocardial infarction and lysis of intracoronary emboli
DB00033Interferon gamma-1bInterferon gamma-1b is used for the treatment of Chronic granulomatous disease and Osteopetrosis.
DB00034Interferon Alfa-2a, RecombinantFor the treatment of chronic hepatitis C, hairy cell leukemia, AIDS-related Kaposi's sarcoma, and chronic myelogenous leukemia. Also for the treatment of oral warts arising from HIV infection.
DB00035Desmopressin- Indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least 2 times per night to void (intranasal). - Indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region (intranasal/parenteral). - Indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5% or mild to moderate classic von Willebrand's Disease (Type I) with factor VIII levels greater than 5% during surgical procedures and postoperatively to maintain hemostasis (parenteral).
DB00036Coagulation factor VIIa Recombinant HumanFor treatment of hemorrhagic complications in hemophilia A and B
DB00038OprelvekinIncreases reduced platelet levels due to chemotherapy
DB00039PaliferminFor treatment of oral mucositis associated with chemotherapy and radiation therapy.
DB00040Glucagon recombinantFor treatment of severe hypoglycemia, also used in gastrointestinal imaging
DB00041AldesleukinFor treatment of adults with metastatic renal cell carcinoma.
DB00042Botulinum Toxin Type BFor the treatment of patients with cervical dystonia to reduce the severity of abnormal head position and neck pain associated with cervical dystonia.
DB00043OmalizumabFor treatment of asthma caused by allergies
DB00050CetrorelixFor the inhibition of premature LH surges in women undergoing controlled ovarian stimulation
DB00051AdalimumabFor treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and Crohn's disease.
DB00054AbciximabAbciximab is indicated as an adjunct to percutaneous coronary intervention for the prevention of cardiac ischemic complications in patients undergoing percutaneous coronary intervention and in patients with unstable angina not responding to conventional medical therapy when percutaneous coronary intervention is planned within 24 hours. Abciximab is intended for use with aspirin and heparin and has been studied only in that setting.
DB00055Drotrecogin alfaFor reduction of mortality in patients with severe sepsis.
DB00056Gemtuzumab ozogamicinIndicated for the treatment of patients with CD33 positive acute myeloid leukemia in first relapse who are 60 years of age or older and who are not considered candidates for other cytotoxic chemotherapy. Indicated for the treatment of patients aged 2 years and older with CD33-positive AML who have experienced a relapse or who have not responded to initial treatment (refractory).
DB00057Indium In-111 satumomab pendetideFor diagnosis of extrahepatic malignant cancers
DB00058Alpha-1-proteinase inhibitorFor chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
DB00060Interferon beta-1aFor treatment of relapsing/remitting multiple sclerosis, also for condyloma acuminatum
DB00062Human Serum AlbuminAlbuminex solution is indicated for adults and children for hypovolemia, ascites, hypoalbuminemia including from burns, acute nephrosis, acute respiratory distress syndrome and cardipulmonary bypass [F229].
DB00065Infliximab* Indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult or pediatric (≥ 6 years of age) patients with moderately to severely active **Crohn’s disease** who have had an inadequate response to conventional therapy * Indicated for reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing **Crohn’s disease**. * Indicated for reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult or pediatric (≥ 6 years of age) patients with moderately to severely active **ulcerative colitis** who have had an inadequate response to conventional therapy. * Indicated for, in combination with methotrexate, reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active **rheumatoid arthritis**. * Indicated for reducing signs and symptoms in patients with active **ankylosing spondylitis**. * Indicated for reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in patients with **psoriatic arthritis**. * Indicated for the treatment of adult patients with chronic severe (i.e., extensive and/or disabling) **plaque psoriasis** who are candidates for systemic therapy and when other systemic therapies are medically less appropriate.
DB00066FollitropinIn women having been diagnosed with primary ovarian failure, it is used in combination with human chorionic gonadotropin (hCG) to assist in ovulation and fertility. In men with hypogonadotrophic hypogonadism, it is used to induce spermatogenesis. Follitropin may also be used to cause the ovary to produce several follicles, which can then be harvested for use in gamete intrafallopian transfer (GIFT) or in vitro fertilization (IVF).
DB00067VasopressinFor the treatment of enuresis, polyuria, diabetes insipidus, polydipsia and oesophageal varices with bleeding
DB00068Interferon beta-1bInterferon beta-1b is a drug used for the treatment of relapsing/remitting multiple sclerosis. It has been shown to slow the advance of the disease as well as to decrease the frequency of attacks.
DB00069Interferon alfacon-1For the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma
DB00070HyaluronidaseFor increase of absorption and distribution of other injected drugs and for rehydration.
DB00071Insulin PorkFor the treatment of type I and II diabetes mellitus.
DB00072TrastuzumabFor treatment of early stage HER2-positive breast cancer, or metastatic breast cancer that substantially overexpress HER2.
DB00073RituximabFor treatment of CD20-positive non-Hodgkins lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis.
DB00074BasiliximabFor prophylactic treatment of kidney transplant rejection
DB00075MuromonabFor treatment of organ transplant recipients, prevention of organ rejection
DB00078Ibritumomab tiuxetanFor treatment of non-Hodgkin's lymphoma
DB00081TositumomabFor treatment of non-Hodgkin's lymphoma (CD20 positive, follicular)
DB00083Botulinum Toxin Type AFor the treatment of cervical dystonia in adults to decrease the severity of abnormal head position and neck pain associated with cervical dystonia. Also for the treatment of severe primary axillary hyperhidrosis that is inadequately managed with topical agents and for the treatment of strabismus and blepharospasm associated with dystonia, including benign essential blepharospasm or VII nerve disorders in patients 12 years of age and above. Also used cosmetically to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows (glabellar lines) as well as for the treatment of excessive underarm sweating.
DB00086StreptokinaseFor the treatment of acute evolving transmural myocardial infarction, pulmonary embolism, deep vein thrombosis, arterial thrombosis or emolism and occlusion of arteriovenous cannulae
DB00087AlemtuzumabAlemtuzumab (Campath) is a monoclonal antibody therapy used for treatment of B-cell chronic lymphocytic leukemia.
DB00089Capromab pendetideFor diagnosis of prostate cancer and detection of intra-pelvic metastases.
DB00092AlefaceptAs an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
DB00093FelypressinFor use as an alternative to adrenaline as a localising agent, provided that local ischaemia is not essential.
DB00095EfalizumabFor the treatment of adult patients with moderate to severe chronic plaque psoriasis, who are candidates for phototherapy or systemic therapy.
DB00098Antithymocyte immunoglobulin (rabbit)For prevention of renal transplant rejection
DB00099FilgrastimFilgrastim is used in patients with acute myeloid leukemia receiving induction or consolidation chemotherapy. It is also used in cancer patients receiving bone marrow transplant. In general, filgrastim increases neutrophil counts in order to decrease the risk of infection or duration of neutropenia in the aforementioned patient populations. Infection and neutropenia are adverse events associated with chemotherapy. Furthermore, filgrastim is also indicated for patients with severe chronic neutropenia. It mobilizes hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis to allow for a more rapid engraftment. Tbo-filgrastim has a narrower indication profile than Neupogen - it is a leukocyte growth factor indicated for the reduction in the duration of severe neutropenia in patients with non-myeloid malignancies.
DB00102BecaplerminFor topical treatment of skin ulcers (from diabetes)
DB00103Agalsidase betaFor treatment of Fabry's disease (alpha-galactosidase A deficiency)
DB00105Interferon Alfa-2b, RecombinantFor the treatment of hairy cell leukemia, malignant melanoma, and AIDS-related Kaposi's sarcoma.
DB00108NatalizumabFor treatment of multiple sclerosis.
DB00109EnfuvirtideEnfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS.
DB00110PalivizumabFor prophylaxis of respiratory diseases casued by respiratory syncytial virus.
DB00111DaclizumabZenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection
DB00112BevacizumabAs part of combination therapy for metastatic colorectal cancer and HER2-negative metastatic breast cancer.
DB00113Technetium Tc-99m arcitumomabFor imaging colorectal tumors
DB00155L-CitrullineUsed for nutritional supplementation, also for treating dietary shortage or imbalance.
DB00183PentagastrinUsed as a diagnostic aid for evaluation of gastric acid secretory function
DB00556PerflutrenUsed as an ultrasound contrast imaging in cardiology and radiology.
DB00644GonadorelinFor evaluating the functional capacity and response of the gonadotropes of the anterior pituitary also for evaluating residual gonadotropic function of the pituitary following removal of a pituitary tumor by surgery and/or irradiation.
DB00666NafarelinFor treatment of central precocious puberty (true precocious puberty, GnRH-dependent precocious precocity, complete isosexual precocity) in children of both sexes and for the treatment of endometriosis.
DB00781Polymyxin B SulfateFor treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa.
DB00803ColistinFor the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.
DB00855Aminolevulinic acidAminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
DB01111ColistimethateFor the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.
DB01229PaclitaxelUsed in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.
DB01257EculizumabFor the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
DB01269PanitumumabFor the treatment of EGFR-expressing, metastatic colorectal carcinoma that is refractory to fluoropyrimidine-, oxaliplatin-, and irinotecan- containing chemotherapy regimens.
DB01270RanibizumabFor the treatment of patients with macular edema after retinal vein occlusion, age-related macular degeneration (wet), and diabetic macular edema.
DB01277MecaserminFor the long-term treatment of growth failure in pediatric patients with Primary IGFD or with GH gene deletion who have developed neutralizing antibodies to GH. It is not indicated to treat Secondary IGFD resulting from GH deficiency, malnutrition, hypothyroidism or other causes; it is not a substitute for GH therapy.
DB01278PramlintideFor the treatment of type 1 and type 2 diabetes mellitus as an adjunct to preprandial insulin therapy in patients without adequate glycemic control of insulin therapy.
DB01279GalsulfaseFor the treatment of adults and children with Mucopolysaccharidosis VI.
DB01281AbataceptFor the management of the signs and symptoms of moderate-to-severe active rheumatoid arthritis, inducing major clinical response, slowing the progression of structural damage, and improving physical function in adult patients. It is indicated both as a monotherapy and for use in combination with a continued regimen of DMARDs (not including TNF antagonists). Also used for the management of the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in children.
DB01284TetracosactideFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
DB01285CorticotropinFor use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency.
DB01309Insulin GlulisineFor the treatment of Type 1 and 2 diabetes mellitus. Should be used in regimens including a long-acting or basal insulin analogue unless it is used in a continuous infusion pump. May be used with oral antidiabetic agents.
DB01373CalciumCalcium plays a vital role in the anatomy, physiology and biochemistry of organisms and of the cell, particularly in signal transduction pathways. It is vital in cell signaling, muscular contractions, bone health, and signalling cascades.
DB01584ThyroglobulinFor the treatment of hypothyroidism (deficiency in the production of thyroid hormone).
DB01853Bacteriochlorophyll ANot Available
DB02137Molybdenum CofactorNot Available
DB02261Platelet Activating FactorNot Available
DB02638TerlipressinCommonly used to stop bleeding of varices in the food pipe (oesophagus).
DB04894VapreotideFor the treatment of esophageal variceal bleeding in patients with cirrhotic liver disease and has also shown efficacy in the treatment of patients with AIDS-related diarrhea.
DB04899NesiritideFor the intravenous treatment of patients with acutely decompensated congestive heart failure who have dyspnea at rest or with minimal activity.
DB04900ThymalfasinIndicated as an adjuvant for influenza vaccine in elderly patients and as an adjuvant for both influenza and hepatitis B vaccines in chronic hemodialysis patients who failed to achieve adequate antibody titers from previous immunization.
DB04901GaliximabInvestigated for use/treatment in lymphoma (non-hodgkin's), psoriasis and psoriatic disorders, bone metastases, multiple myeloma, prostate cancer, and rheumatoid arthritis.
DB04914G17DTIntended for the treatment of various forms of cancer.
DB04921DirucotideFor the treatment of multiple sclerosis (MS).
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB04931AfamelanotideInvestigated for use/treatment in actinic keratosis, keratoses, skin cell studies, and skin infections/disorders.
DB04949PexelizumabFor the treatment of inflammation during cardiac surgery.
DB04956AfelimomabInvestigated for use/treatment in sepsis and septicemia.
DB04958EpratuzumabInvestigated for use/treatment in leukemia (lymphoid), lymphoma (non-hodgkin's), and systemic lupus erythematosus.
DB04962BectumomabInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB04964OregovomabInvestigated for use/treatment in ovarian cancer.
DB04985TigapotideFor the treatment of late stage Hormone Refractory Prostate Cancer (HRPC) for which no effective therapy currently exists.
DB04988IGN311Intended for the treatment of various forms of cancer.
DB05006AdecatumumabInvestigated for use/treatment in breast cancer and prostate cancer.
DB05029LancovutideInvestigated for use/treatment in cystic fibrosis and eye disorders/infections.
DB05032REV131Investigated for use/treatment in allergic reaction, allergic rhinitis, and cataracts.
DB05084AbaloparatideInvestigated for use/treatment in postmenopausal osteoporosis to reduce vertebral and/or non-vertebral fractures.
DB05097LabetuzumabLabetuzumab is a humanized monoclonal antibody used to treat cancer. Retrieved from "http://en.wikipedia.org/wiki/Labetuzumab"
DB05098LeptinInvestigated for use/treatment in lipodystrophy and obesity.
DB05101MatuzumabInvestigated for use/treatment in cervical dysplasia/cancer, colorectal cancer, gastric cancer, and lung cancer.
DB05111FontolizumabInvestigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.
DB05115NN344Investigated for use/treatment in diabetes mellitus type 1 and 2.
DB05136BavituximabInvestigated for use/treatment in breast cancer, cancer/tumors (unspecified), HIV infection, hepatitis (viral, C), and solid tumors.
DB05139CR002Investigated for use/treatment in nephropathy.
DB05155CR665Investigated for use/treatment in pain (acute or chronic).
DB05160TopsalysinInvestigated for use/treatment in benign prostatic hyperplasia, cancer/tumors (unspecified), prostate cancer, prostate disorders, and solid tumors.
DB05161ElafinInvestigated for use/treatment in inflammatory disorders (unspecified).
DB05209SYM001Investigated for use/treatment in thrombocytopenia.
DB05258Natural alpha interferonInvestigated for use/treatment in hepatitis (viral, C), leukemia (lymphoid), leukemia (myeloid), leukemia (unspecified), and melanoma.
DB05259GlatiramerFor reduction of the frequency of relapses in patients with Relapsing-Remitting Multiple Sclerosis.
DB05276Hepatitis B Immune GlobulinInvestigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.
DB05299keyhole limpet hemocyaninInvestigated for use/treatment in bladder cancer and solid tumors.
DB05305Cintredekin BesudotoxInvestigated for use/treatment in brain cancer.
DB05319oportuzumab monatoxInvestigated for use/treatment in bladder cancer and head and neck cancer.
DB05332RomiplostimTreatment of chronic immune thrombocytopenic purpura.
DB05336ObiltoxaximabInvestigated for use/treatment in anthrax exposure, bacterial infection, crohn's disease, and graft versus host disease.
DB05344Ciliary neurotrophic factorInvestigated for use/treatment in eye disorders/infections, macular degeneration, and retinal disorders (unspecified).
DB05394CorticorelinInvestigated for use/treatment in brain cancer and neurologic disorders.
DB05396Albinterferon Alfa-2BInvestigated for use/treatment in hepatitis (viral, C).
DB05405XTL-001Investigated for use/treatment in hepatitis (viral, B).
DB05413TifuvirtideInvestigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections and HIV infection.
DB05437RIGScan CR49Investigated for use/treatment in colorectal cancer and solid tumors.
DB05446LJP 1082Investigated for use/treatment in autoimmune diseases, strokes, and thrombosis.
DB05459BriakinumabInvestigated for use/treatment in autoimmune diseases, crohn's disease, multiple sclerosis, psoriasis and psoriatic disorders, and rheumatoid arthritis.
DB05496OtelixizumabInvestigated for use/treatment in diabetes mellitus type 1, pediatric indications, and psoriasis and psoriatic disorders.
DB05550IratumumabInvestigated for use/treatment in lymphoma (unspecified).
DB05555EnokizumabInvestigated for use/treatment in asthma.
DB05578RamucirumabFor use in advanced gastric or gastro-esophageal junction adenocarcinoma as a single agent or in combination with paclitaxel after prior fluoropyrimidine- or platinum-containing chemotherapy.
DB05595FarletuzumabInvestigated for use/treatment in ovarian cancer.
DB05599Fibroblast growth factor-1Investigated for use/treatment in coronary artery disease and peripheral vascular disease.
DB05656VeltuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB05679UstekinumabUstekinumab is indicated for management of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy; or is used alone or in conjunction with methotrexate for the management of active psoriatic arthritis in adults. The FDA approved the use of ustekinumab in September 2016 for the treatment of moderate to severe Crohn's disease. The use of ustekinumab may improve short term clinical response but not clinical remission in moderate to severe Crohn's disease.
DB05718Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
DB05773Trastuzumab emtansineUsed in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment.
DB05777Thrombomodulin AlfaInvestigated for use/treatment in blood preservative, blood (blood forming organ disorders, unspecified), sepsis and septicemia, and thrombosis.
DB05793PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
DB05797TNX-901Investigated for use/treatment in allergic reaction.
DB05819NBI-6024Investigated for use/treatment in diabetes mellitus type 1 and pediatric indications.
DB05833lymphotoxin beta receptorInvestigated for use/treatment in autoimmune diseases.
DB05875substance PInvestigated for use/treatment in acute respiratory distress syndrome (ARDS) and viral infection.
DB05889Inotuzumab ozogamicinIndicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL).
DB05892RI 624Investigated for use/treatment in pain (acute or chronic).
DB05915MYO-029Investigated for use/treatment in muscular dystrophy.
DB05931PegdinetanibInvestigated for use/treatment in cancer/tumors (unspecified) and macular degeneration.
DB05996Glembatumumab vedotinInvestigated for use/treatment in melanoma.
DB06043OlaratumabOlaratumab is indicated, in combination with doxorubicin, for the treatment of adult patients with advanced or mestastatic soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.
DB06049IPH 2101Investigated for use/treatment in leukemia (myeloid) and multiple myeloma.
DB06081CaplacizumabInvestigated for use/treatment in cardiovascular disorders and thrombosis.
DB06101IMC-1C11Investigated for use/treatment in cancer/tumors (unspecified).
DB06116EldelumabInvestigated for use/treatment in ulcerative colitis.
DB06138IRL-1620Investigated for use/treatment in cancer/tumors (unspecified).
DB06162LumiliximabInvestigated for use/treatment in asthma and leukemia (lymphoid).
DB06168CanakinumabUsed in patients 4 years of age and older to treat Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS), which are both part of the Cryopyrin-Associated Periodic Syndromes (CAPS) as well as for patients 2 years of age and older to treat systemic juvenile idiopathic arthritis (SJIA).
DB06186IpilimumabIpilimumab is approved for different conditions such as: * Treatment of unresectable or metastatic melanoma in patients 12 years and older. * Adjuvant treatment of patients with cutaneous melanoma with the pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.[FDA label] In combination with nivolumab, ipilimumab is approved for: * Treatment of patients with intermediate or poor risk, previously untreated advanced renal cell carcinoma * Treatment of 12 years and older patients with MSI-H/dMMR metastatic colorectal cancer with progression after treatment with fluoropyrimidine, oxaliplatin, and irinotecan.[FDA label]
DB06192NimotuzumabInvestigated for use/treatment in head and neck cancer, brain cancer, pediatric indications, pancreatic cancer, lung cancer, and colorectal cancer.
DB06196IcatibantApproved for use in acute attacks of hereditary angioedema (HAE). Investigated for use/treatment in angioedema, liver disease, and burns and burn infections.
DB06241ClenoliximabInvestigated for use/treatment in rheumatoid arthritis.
DB06244TraferminInvestigated for use/treatment in coronary artery disease, peripheral vascular disease, periodontal disease, bone fractures, entero-related fistulae, and diabetic foot ulcers.
DB06245LanoteplaseInvestigated for use/treatment in myocardial infarction.
DB06260AviptadilNot Available
DB06273TocilizumabIndicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). It is also indicated for the treatment of active polyarticular juvenile idiopathic arthritis (PJIA) and active systemic juvenile idiopathic arthritis (SJIA) in patients 2 years of age and older.
DB06310MotavizumabInvestigated for use/treatment in viral infection and pediatric indications.
DB06317ElotuzumabIndicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.
DB06323AZX-100Investigated for use/treatment in scar tissue.
DB06342Coltuximab ravtansineInvestigated for use/treatment in lymphoma (non-hodgkin's).
DB06360LucatumumabInvestigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).
DB06366PertuzumabPertuzumab is indicated for use in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease.
DB06371SiplizumabInvestigated for use/treatment in psoriasis and psoriatic disorders, transplant (rejection), graft versus host disease, lymphoma (unspecified), and leukemia (unspecified).
DB06372RilonaceptRilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout.
DB06379Calcitonin gene-related peptideInvestigated for use/treatment in myocardial infarction, heart disease, and asthma.
DB06399AtaciceptInvestigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
DB06404Human C1-esterase inhibitorFor routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).
DB06434RepiferminInvestigated for use/treatment in bone marrow transplant, ulcers, and inflammatory bowel disease.
DB06467ApolizumabInvestigated for use/treatment in lymphoma (non-hodgkin's), leukemia (lymphoid), and solid tumors.
DB06493VelaferminInvestigated for use/treatment in adverse effects (chemotherapy).
DB06495OnerceptInvestigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
DB06534ThrombopoietinInvestigated for use/treatment in thrombocytopenia.
DB06549LabradimilInvestigated for use/treatment in brain cancer and pediatric indications.
DB06550BivatuzumabInvestigated for use/treatment in cancer/tumors (unspecified) and head and neck cancer.
DB06557LerdelimumabInvestigated for use/treatment in glaucoma and cataracts.
DB06562EmfilerminInvestigated for use/treatment in adverse effects (chemotherapy), reproductive health, and infertility.
DB06576BaminerceptInvestigated for use/treatment in rheumatoid arthritis.
DB06599LexatumumabInvestigated for use/treatment in cancer/tumors (unspecified).
DB06602ReslizumabIndicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype.
DB06606TeplizumabInvestigated for use/treatment in diabetes mellitus type 1.
DB06607CatumaxomabFor use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible [FDA Label].
DB06611PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
DB06612MepolizumabMepolizumab is indicated for add-on maintenance treatment of severe eosinophilic asthma, as identified by blood eosinophils greater than or equal to 150 cells/μl at initiation of treatment or blood eosinophils greater than or equal to 300 cells/μl in the past 12 months, in patients aged 12 years and older. Mepolizumab has been shown to reduce exacerbations of asthma in patients with an exacerbation history
DB06643DenosumabProlia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be used in men with osteoporosis at high risk for fracture or in men receiving androgen deprivation therapy for nonmetastatic prostate cancer to increase bone mass. Xgeva is indicated for the prevention of skeletal-related events in patients with bone metastases from solid tumors.
DB06647VolociximabInvestigated for use/treatment in solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer.
DB06650OfatumumabOfatumumab is indicated for the treatment of patients with chronic lymphocytic leukemia (CLL) refractory to fludarabine and alemtuzumab.
DB06655LiraglutideFor use in/treatment of diabetes mellitus type 2.
DB06663PasireotideFor the treatment of Cushing’s disease, specifically for those patients whom pituitary surgery has not been curative or is not an option.
DB06674GolimumabUsed in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications.
DB06679AmediplaseInvestigated for use/treatment in myocardial infarction and thrombosis.
DB06681BelataceptFor prophylaxis of organ rejection. It is also used concomitantly with basiliximumab for induction therapy, mycophenolate, and corticosteriods in kidney transplant recepients that are seropositive for the Epstein-Barr virus.
DB06692AprotininFor prophylactic use to reduce perioperative blood loss and the need for blood transfusion in patients undergoing cardiopulmonary bypass in the course of coronary artery bypass graft surgery who are at an increased risk for blood loss and blood transfusion.
DB06719BuserelinBuserelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, estrogen-dependent conditions (such as endometriosis or uterine fibroids), and in assisted reproduction.
DB06763SaralasinNot Available
DB06785GanirelixFor the inhibition of premature LH surges in women undergoing controlled ovarian hyperstimulation.
DB06788HistrelinAs the product Supprelin LA (FDA), histrelin is indicated for the treatment of children with central precocious puberty (CPP). As the product Vantas (FDA), histrelin is indicated for the palliative treatment of advanced prostate cancer.
DB06791LanreotideLanreotide is a somatostatin analog approved for treatment of neuroendocrine tumours and acromegaly. (2)
DB06825TriptorelinTriptorelin is indicated for the palliative treatment of advanced prostate cancer.
DB08856DADLENot Available
DB08861DPDPENot Available
DB08869TesamorelinTesamorelin acetate is a synthetic analogue of human hypothalamic Growth Hormone Releasing Factor (hGRF) indicated to induce and maintain a reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
DB08870Brentuximab vedotinSeattle Genetics Announced FDA Approval of ADCETRIS® (Brentuximab Vedotin) in combination with chemotherapy for adults with previously untreated stage III or IV Classical Hodgkin Lymphoma in March 2018 [L1737, L1739]. Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not ASCT candidates [FDA label], [L1737]. Systemic anaplastic large cell lymphoma after failure of at least one prior multi-agent chemotherapy regimen [FDA label].
DB08879BelimumabAdjunct treatment for auto-antibody-positive active systemic lupus erythematosus.
DB08885AfliberceptThe opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
DB08900TeduglutideTreatment of short bowel syndrome (SBS), malabsorption associated with the removal of the intestine, in adults patients who are dependent on parenteral support.
DB08902RaxibacumabRaxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate.
DB08904Certolizumab pegolReducing signs and symptoms of Crohn's disease and treatment of moderately to severely active rheumatoid arthritis (RA).
DB08935ObinutuzumabObinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
DB09029SecukinumabFor the treatment of moderate to severe plaque psoriasis in patients that are candidates for systemic therapy or phototherapy.
DB09033VedolizumabVedolizumab is indicated for adult patients with moderately to severely active UC or CD who have had an inadequate response with, lost response to, or were intolerant to a tumor necrosis factor (TNF) blocker or immunomodulator; or had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroids.
DB09035NivolumabNivolumab is indicated for the treatment of unresectable or metastatic melanoma for patients who no longer respond to treatment with other drugs. It is intended for use in patients who have been previously treated with ipilimumab and is used for melanoma patients after treatment with ipilimumab and a BRAF inhibitor in patients whose tumors express BRAF V600 gene mutations. Historically there have been very few effective treatments for advanced melanoma, which is why this product was approved under an FDA accelerated program to allow earlier patient access.
DB09036SiltuximabSiltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive.
DB09037PembrolizumabPembrolizumab is indicated for the treatment of: -Patients with unresectable or metastatic melanoma.[FDA label] -As a single therapy, pembrolizumab is indicated for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors have high PD-L1 expression [(Tumor Proportion Score (TPS) ≥50%)] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.[F137] -As a single therapy, pembrolizumab is indicated for first-line treatment of patients with metastatic non-small cell lung cancer whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to treatment.[F137] The following indications present the status of accelerated approval based on tumor response rate and durability of the response and thus, the approval of this indications are contingent upon verification and description of clinical benefit in confirmatory trials. -Patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS > 1) as determined by an FDA-approved test.[L2955] -In combination with pemetrexed and carboplatin, is indicated for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer.[F137] -Patients with recurrent or metastatic head and neck squamous cell carcinoma with disease progression on or after platinum-containing chemotherapy.[F137] -Treatment of adults and pediatric patients with refractory classical Hodgkin lymphoma or who have relapsed after 3 or more prior lines of therapy.[F137] -Treatment of adult and pediatric patients with refractory primary mediastinal large B-cell lymphoma or who have relapsed after 2 or more prior lines of therapy.[F137] -Treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy.[F137] -Patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy.[F137] -Treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient with solid tumors that have progressed following previous treatment and colorectal cancer that has progressed following treatment with fluoropyrimidine, oxaliplatin, and irinotecan.[F137] -Patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (CPS >1) as determined by an FDA-approved test, with disease progression on or after two or more prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and if appropriate, HER2/neu-targeted therapy.[F137]
DB09043AlbiglutideIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB09045DulaglutideIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB09046MetreleptinMetreleptin is indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
DB09052BlinatumomabIndicated for the treatment of Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).
DB09067Corticorelin ovine triflutateCorticorelin is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome.
DB09077DinutuximabDinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.
DB09099SomatostatinFor the symptomatic treatment of acute bleeding from esophageal varices. Other treatment options for long-term management of the condition may be considered if necessary, once initial control has been established.
DB09103AncestimAncestim, in combination with filgrastim, is indicated for the setting of autologous peripheral blood progenitor cell transplantation in patients at risk of poor peripheral blood progenitor cell mobilisation.[L1090] The use of ancestim with filgrastim will generate a sustained increase in the number of peripheral blood progenitor cells capable of engraftment. It is used for mobilization of progenitor cells from the bone marrow to the peripheral blood with or withouth mobilizing chemotherapy. The harvested progenitor cells can be used for transplant following myelosuppressive or myeloablative therapies.[L1089]
DB09105Asfotase AlfaIndicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP).
DB09107Methoxy polyethylene glycol-epoetin betaFor the treatment of patients with anaemia associated with chronic kidney disease. Not a substitute for RBC transfusion if immediate correction of anemia is required.
DB09109Turoctocog alfaTuroctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A.[L1105] The treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative management.[L1106] Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. This disease is manifested as excessive spontaneous or trauma-driven bleeding. The coagulation factor VIII is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the X chromosome.[A31505]
DB09122Peginterferon beta-1aFor the treatment of patients with relapsing forms of multiple sclerosis.
DB09126Chorionic Gonadotropin (Human)For the treatment of prepubertal cryptorchidism (not due to anatomical obstruction), for the treatment of selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males and for the induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins.
DB09141Protamine sulfateProtamine sulfate is usually administered to reverse the large dose of heparin administered during certain surgeries, especially heart surgery.
DB09221PolaprezincPeptic ulcer disease, dyspepsia [L1308].
DB09222Fibrinogen HumanFor the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.
DB09264IdarucizumabFor use in patients treated with Dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding.
DB09302AlirocumabAlirocumab is indicated as an adjunct to diet and maximally tolerated statin therapy in adults who require additional LDL-cholesterol (LDL-C) lowering due to heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease.
DB09303EvolocumabFor the treatment of heterozygous/homozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in patients on maximum tolerated statin therapy requiring additional LDL-cholesterol lowering.
DB09312Antilymphocyte immunoglobulin (horse)For prevention of renal transplant rejection and for the treatment of aplastic anemia.
DB09331DaratumumabFor the treatment of patients with multiple myeloma who have received at least three prior lines of therapy (a proteasome inhibitor (PI) and an immunomodulatory agent) or who are double-refractory to a PI and an immunomodulatory agent. This indication was approved by accelerated approval based on response rate.
DB09349Gastric intrinsic factorIntrinsic factor is not currently available in any FDA or Health Canada approved products. However, it is currently in the marketed (but unapproved) product Hematogen in combination with cyanocobalamin (synthetic Vitamin B12), ferrous fumarate, and ascorbic acid for the treatment of anemias responsive to oral iron therapy.
DB09421ProtirelinNot Available
DB09527Secretin porcineNot Available
DB09559NecitumumabNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). It is not indicated for treatment of non-squamous NSCLC.
DB10516CaseinNot Available
DB10789Bordetella pertussis pertactin antigenNot Available
DB11095DesirudinIndicated as prophylaxis of deep vein thrombosis for patients undergoing hip replacement surgery.
DB11209Iron protein succinylateNot Available
DB11242GelatinGelatin is used for weight loss and for treating osteoarthritis, rheumatoid arthritis, and brittle bones (osteoporosis). Some people also use it for strengthening bones, joints, and fingernails. Gelatin is also used for improving hair condition and to shorten the recovery after exercise and sports-related injury [L2113]. Gelatin is used in preparations of foods, cosmetics, and medicine [L2113]. Plasma volume expander in hypovolaemic shock [L2115]. Haemostatic [L2115]. Gelatin-based hydrogels are being used in drug delivery and tissue engineering because they are able to promote cell adhesion and proliferation. In addition, these hydrogels can be used as wound dressings because of their attractive fluid absorbance properties. Manufacturing technologies such as ultraviolet stereolithography and two-photon polymerization can be used to prepare structures containing photosensitive gelatin-based hydrogels [L2111].
DB11298ThioredoxinNot Available
DB11300ThrombinBovine thrombin is a topical thrombin indicated to aid hemostasis whenever oozing blood and minor bleeding from capillaries and small venules is accessible and control of bleeding by standard surgical techniques (like suture, ligature, or cautery) is ineffective or impractical [FDA Label]. Additionally, topical bovine thrombin can also be used in combination with an absorbable gelatin sponge, USP [FDA Label].
DB11311ProthrombinFor use in the emergency reversal of coagulation factor deficiency in patients receiving vitamin K antagonist therapy. Prothrombin is administered as part of a cocktail containing several coagulation factors.
DB11312Protein CProtein C Concentrate is indicated for pediatric and adult patients with severe congenital Protein C deficiency for the prevention and treatment of venous thrombosis and purpura fulminans.
DB11330Factor IX Complex (Human)Factor IX Complex is indicated for the prevention and control of hemorrhagic episodes in hemophilia B patients. It is also indicated for the urgent reversal of acquired coagulation factor deficiency induced by Vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with acute major bleeding or who require rapid reversal of therapy.
DB11510DeslorelinNot Available
DB11569Ixekizumab Ixekizumab is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DB11595AtezolizumabFor the treatment of patients with locally advanced or metastatic urothelial carcinoma who: 1) have disease progression during or following platinum-containing chemotherapy, and 2) have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.
DB11598Antithrombin III humanAntithrombin III human is a human antithrombin (AT) indicated in patients with hereditary antithrombin deficiency for the treatment and prevention of thromboembolism and prevention of peri-operative and peri-partum thromboembolism
DB11621Human Varicella-Zoster Immune GlobulinIndicated for preventing and reducing the severity of chicken pox (varicella zoster virus) infections in high risk individuals within 4 days of exposure to varicella zoster virus.
DB11624Epoetin deltaNot Available
DB11631Eptotermin AlfaNot Available
DB11639Dibotermin alfa- indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation [FDA Label]. - indicated for single-level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non-operative treatment for this condition [L1391].
DB11646ConatumumabNot Available
DB11653BremelanotideNot Available
DB11657TabalumabNot Available
DB11668Rusalatide acetateNot Available
DB11680FiclatuzumabNot Available
DB11685FigitumumabNot Available
DB11690VonapanitaseNot Available
DB11695CarnosineNot Available
DB11700SetmelanotideNot Available
DB11714DurvalumabDurvalumab is indicated for patients with urothelial carcinoma, such as urinary bladder, urethra or ureter cancer. Patients with prolonged disease progression due to failed platinum-based chemotherapy such as cisplatin and carboplatin are most likely to benefit from durvalumab treatment. Its clinical effectiveness is especially enhanced in PD-L1-positive patient groups [A19123].
DB11715BapineuzumabNot Available
DB11724BombesinNot Available
DB11746OnartuzumabNot Available
DB11756SolanezumabNot Available
DB11767SarilumabIndicated for modere to severe reactive RA in adult patients who are irresponsive, respond inadequately or present intolerance to disease-modifying anti-rheumatic drugs (DMARDs) or tumor necrosis factor (TNF) antagonists. It is indicated to be used in combination with methotrexate (MTX) or as a monotherapy when there is intolerance to MTX or MTX administration is inappropriate.
DB11771TremelimumabNot Available
DB11776BrodalumabBrodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
DB11788Neuropeptide YNot Available
DB11803SirukumabNot Available
DB11826LampalizumabNot Available
DB11834GuselkumabIndicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
DB11840DalotuzumabNot Available
DB11842Angiotensin IIAngiotensin II is a vasoconstrictor indicated for increasing blood pressure in adults with septic or other distributive shock [FDA Label].
DB11849EmibetuzumabNot Available
DB11856LigelizumabNot Available
DB11857SeribantumabNot Available
DB11862LandogrozumabNot Available
DB11866RomosozumabNot Available
DB11945AvelumabIndicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC).
DB11955AvoterminNot Available
DB11959CrenezumabNot Available
DB11972RilotumumabNot Available
DB11975TAK-448Not Available
DB11976AnifrolumabNot Available
DB11988OcrelizumabIndicated for the treatment of adult patients with relapsing or primary progressive forms of multiple sclerosis [FDA Label].
DB11997Interleukin-7Not Available
DB12003Thymosin beta-4Not Available
DB12034GantenerumabNot Available
DB12038UlinastatinNot Available
DB12053VisilizumabNot Available
DB12056TrebananibNot Available
DB12075NagrestipenNot Available
DB12088TT-232Not Available
DB12089Lorvotuzumab mertansineNot Available
DB12090PatritumabNot Available
DB12102FulranumabNot Available
DB12104TarextumabNot Available
DB12118SotaterceptNot Available
DB12119GevokizumabNot Available
DB12126BradykininNot Available
DB12132Vanutide cridificarNot Available
DB12142DuligotuzumabNot Available
DB12159DupilumabDupilumab is a monoclonal antibody designed for the treatment of atopic diseases such as eczema.
DB12169TralokinumabNot Available
DB12182BinetrakinNot Available
DB12189EtrolizumabNot Available
DB12205GanitumabNot Available
DB12213EtaracizumabNot Available
DB12240Polatuzumab VedotinNot Available
DB12246InclacumabNot Available
DB12250CixutumumabNot Available
DB12261AscrinvacumabNot Available
DB12274AducanumabNot Available
DB12330BlisibimodNot Available
DB12335TanezumabNot Available
DB12349DulanerminNot Available
DB12363DusigitumabNot Available
DB12396FresolimumabNot Available
DB12409Vatreptacog alfaNot Available
DB12431MuplestimNot Available
DB12456BococizumabNot Available
DB12460ConberceptNot Available
DB12489Mirvetuximab SoravtansineNot Available
DB12495SelepressinNot Available
DB12498MogamulizumabNot Available
DB12525MolgramostimNot Available
DB12530InebilizumabNot Available
DB12534MavrilimumabNot Available
DB12560BlosozumabNot Available
DB12568TecemotideNot Available
DB12584BimagrumabNot Available
DB12589DacetuzumabInvestigated for use/treatment in lymphoma (non-hodgkin's) and multiple myeloma.
DB12602PentetreotideNot Available
DB12609TovetumabNot Available
DB12616SpriferminNot Available
DB12620Nerve Growth FactorNot Available
DB12652Endothelin-1Not Available
DB12684AviscumineNot Available
DB12698IbalizumabIndicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in highly treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen [FDA label]. The approval of Trogarzo was supported by a clinical trial of 40 treatment-experienced adults with MDR HIV-1 infection who persistently had elevated levels of HIV RNA in their blood despite heavy antiretroviral therapy. The majority of study patients had previously been treated with ≥10 antiretroviral medications [L1554].
DB12699BalugrastimNot Available
DB12701IntetumumabNot Available
DB12718CarlumabNot Available
DB12726MonteplaseNot Available
DB12732FirategrastNot Available
DB12734DemcizumabNot Available
DB12738TiplimotideNot Available
DB12755Zoptarelin doxorubicinNot Available
DB12775AbituzumabNot Available
DB12777SomatoprimNot Available
DB12807Naptumomab EstafenatoxNot Available
DB12815CrotedumabNot Available
DB12820ConcizumabNot Available
DB12822Pancreatic PolypeptideNot Available
DB12826DepatuxizumabNot Available
DB12835Olipudase alfaNot Available
DB12844RontalizumabNot Available
DB12845AmatuximabNot Available
DB12849ClazakizumabNot Available
DB12880Interleukin-10Not Available
DB12891OzanezumabNot Available
DB12893Sacituzumab govitecanNot Available
DB12909Factor XIII (human)Factor XIII (Human), available as the commercially available product Corifact, is approved by the Food and Drug Administration for routine prophylactic treatment and peri-operative management of surgical bleeding in adult and pediatric patients with congenital FXIII deficiency [FDA Label].
DB12938IsoxaflutoleNot Available
DB12943MilatuzumabNot Available
DB12976RobatumumabNot Available
DB13033Urocortin-2Not Available
DB13045RacotumomabNot Available
DB13127OlokizumabNot Available
DB13133Von Willebrand Factor HumanThe vWF and Factor VIII complex is indicated for the prevention of excessive bleeding during and after minor and major surgery in adult and pediatric von Willebrand disease patients. It is also indicated for the on-demand treatment and control of bleeding episodes.[L1880] The von Willebrand disease is an inherited disorder characterized by the deficiency or misfunction of the von Willebrand factor (vWF). Due to this deficiency, the blood cannot clot properly and the patients that present this disease are prone to prolonged or excessive bleeding. There are three types of this disease, and type 3 is an autosomal recessive inherited disorder marked by very low or absent levels of vWF.[L1867]
DB13144LenograstimThe drug is used to reduce the risk of life-threatening infection in patients with neutropenia, particularly after cytotoxic chemotherapy. Lenograstim is indicated as a treatment to reduce the duration of neutropenia and the severity of infections in patients with non-myeloid malignancy who have undergone autologous or allogeneic bone marrow transplantation, or treatment with established cytotoxic chemotherapy and in addition to reduce the incidence of infection associated with established cytotoxic chemotherapy. Lenograstim is also indicated to mobilise peripheral blood progenitor cells (PBPCs) with Lenograstim alone, or after myelosuppressive chemotherapy, in order to accelerate haematopoietic recovery by infusion of such cells, after myelosuppressive or myeloablative therapy. Lenograstim is also indicated to accelerate the engraftment of these cells after their reinfusion. GRANOCYTE is also indicated for the treatment of severe chronic neutropenia including congenital agranulocytosis (Kostmann's syndrome).
DB13148Coagulation factor X humanIndicated in adults and children (aged 12 years and above) with hereditary Factor X deficiency for on-demand treatment and control of bleeding episodes, or for perioperative management of bleeding in patients with mild hereditary Factor X deficiency [FDA Label].
DB13149Protein S humanFor use in the emergency reversal of coagulation factor deficiency in patients recieving vitamin K antagonist therapy [FDA Label]. Protein S is administered as part of a cocktail containing several other coagulation factors.
DB13150Coagulation factor VII humanMay be administered in cases of uncontrolled bleeding. Factor VII alone can be used in the treatment of congenital hemophilia A or B, acquired hemophilia, congenital factor VII deficiency, and Glanzmann's thrombasthenia. Off label use in the treatment of refractory bleeding after cardiac surgery and warfarin related intracerebral hemorrhage. Brands for human factor VII are currently only in combination with other vitamin K coagulation factors and can be used to reverse vitamin K antagonist activity in patients with acute major bleeds or for urgent surgery/invasive procedures.
DB13192Antihemophilic factor humanThe human antihemophilic factor is indicated for the cases of hemophilia A, also known as classical hemophilia for the prevention and control of hemorrhagic episodes.[L1055] If surgery is needed in patients with hemophilia A there is a need of correction of the clotting abnormality. In this cases, the human antihemophilic factor may be administered followed by intermittent maintenance doses.[L1053] The hemophilia A is characterized by the deficiency of the coagulation factor VIII that results in prolonged blood flow after injury or surgery as well as recurrent bleeding.[T56]
DB13200LipegfilgrastimIndicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) [L2441].
DB13201Trenonacog alfaNot Available
DB13257Ferrous sulfateFor the prevention and treatment of iron deficiency anemia [L2252].
DB13375EdrecolomabNot Available
DB13864Hemoglobin crosfumarilNot Available
DB13886Human cytomegalovirus immune globulinIt is used to prevent cytomegalovirus (CMV) disease after organ transplant [L2225]. Cytomegalovirus Immune Globulin Intravenous (Human) is indicated for the prophylaxis of cytomegalovirus disease associated with transplantation of kidney, lung, liver, pancreas, and heart [FDA label]. In transplants of these organs other than the kidney from CMV seropositive donors into seronegative recipients, prophylactic CMV-IGIV should be considered in combination with ganciclovir [FDA label].
DB13923EmicizumabThe main function of Emicizumab is the prevention of bleeding episodes. Thus, Emicizumab is approved for the routine prophylaxis of patients with hemophilia A that present Factor VIII inhibitors. Hemophilia A is a deficiency of coagulation Factor VIII which causes a serious bleeding disorder. The standard treatment is done with the administration of recombinant or serum-deriver Factor VIII which induces the formation of anti-factor VIII alloantibodies (Factor VIII inhibitors) and renders the standard treatment ineffective.[A31286]
DB13928SemaglutideSemaglutide is indicated to improve glycemic control in adults with type 2 diabetes mellitus as an adjunct of diet and exercise. The approved therapeutic doses are 0.5 mg and 1 mg.[L1068] Diabetes mellitus type 2 is a long-term metabolic disorder characterized by high blood sugar, insulin resistance and lack of insulin. Its onset is determined by the loss ability of beta cells to respond to an increased plasma glucose. This disease is predominantly caused by lifestyle factors like overweight and obesity. The key feature on type 2 diabetes is the presence of insulin resistance which reduced the capacity of insulin to exert its functions at normal at any given concentration. The secretion of insulin is stimulated by the action of incretins in the gut like glucagon-like peptide 1, which also delays gastric emptying and induces satiety, and glucose-dependent insulinotropic polypeptide.[T59]
DB13933Nonacog beta pegolNonacog beta pegol is indicated for the use in adults and children with hemophilia B for control and prevention of bleeding episodes, routine prophylaxis and perioperative management.[L1100] In the EMA approval, it is also indicated for on-demand treatment of bleeding episodes.[L1099] Hemophilia B is characterized by a deficiency in the coagulation factor IX which results in prolonged oozing after injuries and delayed or recurring bleeding prior wound healing. Hemophilia B patients present more frequent bleeding episodes during childhood and adolescence than in adulthood.[T56]
DB13968Plasma protein fraction (human)PPFh is used as a replacement therapy in patients with complex deficiencies of coagulation factors such as coagulopathy. It is also used as a substitution therapy in emergency cases of factor deficiencies, for rapid reversal of the effects of oral anticoagulants or in dangerous hemorrhages during fibrinolytic therapy. PPFh can be used in therapeutic plasma exchange procedures including thrombotic thrombocytopenic purpura.[L2264] PPFh can be used in the treatment of shock where there is a predominant loss of plasma fluids and not red blood cells.[L2261]
DB13976SulesomabNot Available
DB13979BesilesomabBesilesomab is radiolabelled with sodium pertechnetate (Tc99m) solution to develop technetium (Tc99m) besilesomab solution. This solution is indicated in adults for scintigraphic imaging - in conjunction with other appropriate imaging modalities, when possible - in determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis [FDA Label]. When utilized as such, this medicinal product is for diagnostic use only [FDA Label].
DB13999Moroctocog alfaMoroctocog Alfa is approved by Health Canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia). Moroctocog Alfa is also approved by the European Medicines Agency for the treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital factor VIII deficiency).
DB14004TildrakizumabModerate-severe plaque psoriasis [L1858], [FDA label].
DB14027TaspoglutideNot Available
DB14039ErenumabErenumab is indicated for the preventative treatment of migraine in adults [FDA Label].
DB14041FremanezumabThe ongoing trials for fremanezumab are for episodic and chronic migraine prevention and also for cluster headache [A33114].
DB14131Basic Fibroblast Growth FactorBasic Fibroblast Growth Factor is not currently approved for any FDA or Health Canada approved indications.
DB14145NepiderminNot Available
DB14211FanolesomabNot Available
DB14472Insulin-like growth factor IINot Available
DB14473Beroctocog alfaNot Available
DrugDrug NameTargetType
DB00001LepirudinProthrombintarget
DB00002CetuximabEpidermal growth factor receptortarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00002CetuximabComplement C1r subcomponenttarget
DB00002CetuximabComplement C1q subcomponent subunit Atarget
DB00002CetuximabComplement C1q subcomponent subunit Btarget
DB00002CetuximabComplement C1q subcomponent subunit Ctarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00002CetuximabComplement C1s subcomponenttarget
DB00002CetuximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00002CetuximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00003Dornase alfaDNAtarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
DB00004Denileukin diftitoxCytokine receptor common subunit gammatarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit betatarget
DB00005EtanerceptTumor necrosis factortarget
DB00005EtanerceptLymphotoxin-alphatarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00005EtanerceptComplement C1r subcomponenttarget
DB00005EtanerceptComplement C1q subcomponent subunit Atarget
DB00005EtanerceptComplement C1q subcomponent subunit Btarget
DB00005EtanerceptComplement C1q subcomponent subunit Ctarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00005EtanerceptComplement C1s subcomponenttarget
DB00005EtanerceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00005EtanerceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00005EtanerceptTumor necrosis factor receptor superfamily member 1Btarget
DB00005EtanerceptProstaglandin G/H synthase 2enzyme
DB00006BivalirudinProthrombintarget
DB00006BivalirudinMyeloperoxidaseenzyme
DB00007LeuprolideGonadotropin-releasing hormone receptortarget
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 2target
DB00008Peginterferon alfa-2aInterferon alpha/beta receptor 1target
DB00008Peginterferon alfa-2aCytochrome P450 1A2enzyme
DB00009AlteplaseUrokinase plasminogen activator surface receptortarget
DB00009AlteplaseFibrinogen alpha chaintarget
DB00009AlteplasePlasminogentarget
DB00009AlteplasePlasminogen activator inhibitor 1target
DB00010SermorelinGrowth hormone-releasing hormone receptortarget
DB00011Interferon alfa-n1Interferon alpha/beta receptor 2target
DB00011Interferon alfa-n1Interferon alpha/beta receptor 1target
DB00012Darbepoetin alfaErythropoietin receptortarget
DB00013UrokinaseUrokinase plasminogen activator surface receptortarget
DB00013UrokinasePlasminogentarget
DB00013UrokinaseUrokinase-type plasminogen activatortarget
DB00013UrokinaseTissue-type plasminogen activatortarget
DB00013UrokinasePlasminogen activator inhibitor 2target
DB00013UrokinasePlasminogen activator inhibitor 1target
DB00013UrokinasePlasma serine protease inhibitortarget
DB00013UrokinaseNidogen-1target
DB00013UrokinaseLow-density lipoprotein receptor-related protein 2target
DB00013UrokinaseSuppressor of tumorigenicity 14 proteintarget
DB00014GoserelinLutropin-choriogonadotropic hormone receptortarget
DB00014GoserelinGonadotropin-releasing hormone receptortarget
DB00015ReteplaseUrokinase plasminogen activator surface receptortarget
DB00015ReteplaseFibrinogen alpha chaintarget
DB00015ReteplasePlasminogentarget
DB00015ReteplasePlasminogen activator inhibitor 1target
DB00016ErythropoietinErythropoietin receptortarget
DB00017Salmon CalcitoninCalcitonin receptortarget
DB00018Interferon alfa-n3Interferon alpha/beta receptor 1target
DB00018Interferon alfa-n3Interferon alpha/beta receptor 2target
DB00019PegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB00019PegfilgrastimNeutrophil elastasetarget
DB00020SargramostimGranulocyte-macrophage colony-stimulating factor receptor subunit alphatarget
DB00020SargramostimBone marrow proteoglycantarget
DB00020SargramostimInterleukin-3 receptor subunit alphatarget
DB00020SargramostimCytokine receptor common subunit betatarget
DB00020SargramostimSyndecan-2target
DB00021SecretinSecretin receptortarget
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 1target
DB00022Peginterferon alfa-2bInterferon alpha/beta receptor 2target
DB00022Peginterferon alfa-2bCytochrome P450 1A2enzyme
DB00022Peginterferon alfa-2bCytochrome P450 2D6enzyme
DB00025Antihemophilic factor, human recombinantCoagulation factor Xtarget
DB00025Antihemophilic factor, human recombinantPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB00025Antihemophilic factor, human recombinantCoagulation factor IXtarget
DB00025Antihemophilic factor, human recombinantAsialoglycoprotein receptor 2target
DB00025Antihemophilic factor, human recombinant78 kDa glucose-regulated proteintarget
DB00025Antihemophilic factor, human recombinantCalreticulintarget
DB00025Antihemophilic factor, human recombinantCalnexintarget
DB00025Antihemophilic factor, human recombinantProtein ERGIC-53target
DB00025Antihemophilic factor, human recombinantProlow-density lipoprotein receptor-related protein 1target
DB00025Antihemophilic factor, human recombinantMultiple coagulation factor deficiency protein 2target
DB00025Antihemophilic factor, human recombinantvon Willebrand factortarget
DB00025Antihemophilic factor, human recombinantProthrombinenzyme
DB00025Antihemophilic factor, human recombinantVitamin K-dependent protein Cenzyme
DB00026AnakinraInterleukin-1 receptor type 1target
DB00027Gramicidin DMultidrug resistance protein 1transporter
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00028Immune Globulin HumanHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00028Immune Globulin HumanLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00028Immune Globulin HumanHigh affinity immunoglobulin gamma Fc receptor IBtarget
DB00028Immune Globulin HumanComplement C3target
DB00028Immune Globulin HumanComplement C4-Atarget
DB00028Immune Globulin HumanComplement C4-Btarget
DB00028Immune Globulin HumanComplement C5target
DB00029AnistreplaseUrokinase plasminogen activator surface receptortarget
DB00029AnistreplaseFibrinogen alpha chaintarget
DB00029AnistreplasePlasminogentarget
DB00029AnistreplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseUrokinase plasminogen activator surface receptortarget
DB00031TenecteplasePlasminogen activator inhibitor 1target
DB00031TenecteplaseFibrinogen alpha chaintarget
DB00031TenecteplasePlasminogen activator inhibitor 2target
DB00031TenecteplaseTetranectintarget
DB00031TenecteplaseKeratin, type II cytoskeletal 8target
DB00031TenecteplaseAnnexin A2target
DB00031TenecteplaseCalreticulintarget
DB00031TenecteplaseCalnexintarget
DB00031TenecteplaseProlow-density lipoprotein receptor-related protein 1target
DB00031TenecteplasePlasminogentarget
DB00033Interferon gamma-1bInterferon gamma receptor 1target
DB00033Interferon gamma-1bInterferon gamma receptor 2target
DB00033Interferon gamma-1bCytochrome P450 1A2enzyme
DB00034Interferon Alfa-2a, RecombinantInterferon alpha/beta receptor 1target
DB00034Interferon Alfa-2a, RecombinantInterferon alpha/beta receptor 2target
DB00035DesmopressinVasopressin V1a receptortarget
DB00035DesmopressinVasopressin V1b receptortarget
DB00035DesmopressinVasopressin V2 receptortarget
DB00035DesmopressinProstaglandin G/H synthase 1enzyme
DB00035DesmopressinProstaglandin G/H synthase 2enzyme
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor Xtarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factortarget
DB00036Coagulation factor VIIa Recombinant HumanSerine protease hepsintarget
DB00036Coagulation factor VIIa Recombinant HumanTissue factor pathway inhibitortarget
DB00036Coagulation factor VIIa Recombinant HumanVitamin K-dependent gamma-carboxylasetarget
DB00036Coagulation factor VIIa Recombinant HumanCoagulation factor VIItarget
DB00038OprelvekinInterleukin-11 receptor subunit alphatarget
DB00039PaliferminFibroblast growth factor receptor 2target
DB00039PaliferminNeuropilin-1target
DB00039PaliferminFibroblast growth factor receptor 1target
DB00039PaliferminFibroblast growth factor receptor 4target
DB00039PaliferminFibroblast growth factor receptor 3target
DB00039PaliferminBasement membrane-specific heparan sulfate proteoglycan core proteintarget
DB00040Glucagon recombinantGlucagon receptortarget
DB00040Glucagon recombinantGlucagon-like peptide 2 receptortarget
DB00040Glucagon recombinantGlucagon-like peptide 1 receptortarget
DB00041AldesleukinInterleukin-2 receptor subunit betatarget
DB00041AldesleukinInterleukin-2 receptor subunit alphatarget
DB00041AldesleukinCytokine receptor common subunit gammatarget
DB00041AldesleukinProstaglandin G/H synthase 2enzyme
DB00041AldesleukinCytosolic phospholipase A2enzyme
DB00041AldesleukinCytochrome P450 3A4enzyme
DB00041AldesleukinXanthine dehydrogenase/oxidaseenzyme
DB00041AldesleukinCytochrome P450 2E1enzyme
DB00042Botulinum Toxin Type BVesicle-associated membrane protein 1target
DB00042Botulinum Toxin Type BVesicle-associated membrane protein 2target
DB00042Botulinum Toxin Type BSynaptotagmin-2target
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit alphatarget
DB00043OmalizumabHigh affinity immunoglobulin epsilon receptor subunit betatarget
DB00050CetrorelixLutropin-choriogonadotropic hormone receptortarget
DB00050CetrorelixGonadotropin-releasing hormone receptortarget
DB00051AdalimumabTumor necrosis factortarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00051AdalimumabComplement C1r subcomponenttarget
DB00051AdalimumabComplement C1q subcomponent subunit Atarget
DB00051AdalimumabComplement C1q subcomponent subunit Btarget
DB00051AdalimumabComplement C1q subcomponent subunit Ctarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00051AdalimumabComplement C1s subcomponenttarget
DB00051AdalimumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00051AdalimumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin beta-3target
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00054AbciximabComplement C1r subcomponenttarget
DB00054AbciximabComplement C1q subcomponent subunit Atarget
DB00054AbciximabComplement C1q subcomponent subunit Btarget
DB00054AbciximabComplement C1q subcomponent subunit Ctarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00054AbciximabComplement C1s subcomponenttarget
DB00054AbciximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00054AbciximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00054AbciximabIntegrin alpha-IIbtarget
DB00054AbciximabVitronectintarget
DB00055Drotrecogin alfaCoagulation factor VIIItarget
DB00055Drotrecogin alfaCoagulation factor Vtarget
DB00055Drotrecogin alfaPlasminogen activator inhibitor 1target
DB00055Drotrecogin alfaThrombomodulintarget
DB00055Drotrecogin alfaVitamin K-dependent protein Starget
DB00055Drotrecogin alfaCeruloplasmintarget
DB00055Drotrecogin alfaProthrombintarget
DB00055Drotrecogin alfaPlatelet factor 4target
DB00055Drotrecogin alfaPlasma serine protease inhibitortarget
DB00055Drotrecogin alfaSerpin B6target
DB00055Drotrecogin alfaVitamin K-dependent gamma-carboxylasetarget
DB00055Drotrecogin alfaEndothelial protein C receptortarget
DB00056Gemtuzumab ozogamicinMyeloid cell surface antigen CD33target
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00056Gemtuzumab ozogamicinComplement C1r subcomponenttarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Atarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Btarget
DB00056Gemtuzumab ozogamicinComplement C1q subcomponent subunit Ctarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00056Gemtuzumab ozogamicinComplement C1s subcomponenttarget
DB00056Gemtuzumab ozogamicinHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00056Gemtuzumab ozogamicinLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00057Indium In-111 satumomab pendetideTumor-associated glycoprotein 72 (TAG-72)target
DB00058Alpha-1-proteinase inhibitorNeutrophil elastasetarget
DB00060Interferon beta-1aInterferon alpha/beta receptor 1target
DB00060Interferon beta-1aInterferon alpha/beta receptor 2target
DB00065InfliximabTumor necrosis factortarget
DB00066FollitropinFollicle-stimulating hormone receptortarget
DB00067VasopressinVasopressin V1a receptortarget
DB00067VasopressinVasopressin V2 receptortarget
DB00067VasopressinVasopressin V1b receptortarget
DB00067VasopressinCanalicular multispecific organic anion transporter 1transporter
DB00068Interferon beta-1bInterferon alpha/beta receptor 1target
DB00068Interferon beta-1bInterferon alpha/beta receptor 2target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 1target
DB00069Interferon alfacon-1Interferon alpha/beta receptor 2target
DB00070HyaluronidaseTransforming growth factor beta-1target
DB00070HyaluronidaseSerum albumincarrier
DB00070HyaluronidaseHyaluronantarget
DB00071Insulin PorkInsulin receptortarget
DB00071Insulin PorkHLA class II histocompatibility antigen, DQ alpha 2 chaintarget
DB00071Insulin PorkHLA class II histocompatibility antigen, DQ beta 1 chaintarget
DB00071Insulin PorkRetinoblastoma-associated proteintarget
DB00071Insulin PorkCathepsin Dtarget
DB00071Insulin PorkInsulin-like growth factor 1 receptortarget
DB00071Insulin PorkInsulin-degrading enzymetarget
DB00071Insulin PorkNeuroendocrine convertase 2target
DB00071Insulin PorkCarboxypeptidase Etarget
DB00071Insulin PorkNeuroendocrine convertase 1target
DB00071Insulin PorkProtein NOV homologtarget
DB00071Insulin PorkLow-density lipoprotein receptor-related protein 2target
DB00071Insulin PorkInsulin-like growth factor-binding protein 7target
DB00071Insulin PorkSynaptotagmin-like protein 4target
DB00071Insulin PorkCytochrome P450 1A2enzyme
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00072TrastuzumabComplement C1r subcomponenttarget
DB00072TrastuzumabComplement C1q subcomponent subunit Atarget
DB00072TrastuzumabComplement C1q subcomponent subunit Btarget
DB00072TrastuzumabComplement C1q subcomponent subunit Ctarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00072TrastuzumabComplement C1s subcomponenttarget
DB00072TrastuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00072TrastuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00072TrastuzumabReceptor tyrosine-protein kinase erbB-2target
DB00072TrastuzumabEpidermal growth factor receptortarget
DB00072TrastuzumabCytochrome P450 19A1enzyme
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00073RituximabComplement C1r subcomponenttarget
DB00073RituximabComplement C1q subcomponent subunit Atarget
DB00073RituximabComplement C1q subcomponent subunit Btarget
DB00073RituximabComplement C1q subcomponent subunit Ctarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00073RituximabComplement C1s subcomponenttarget
DB00073RituximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00073RituximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00073RituximabB-lymphocyte antigen CD20target
DB00074BasiliximabInterleukin-2 receptor subunit alphatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00074BasiliximabComplement C1r subcomponenttarget
DB00074BasiliximabComplement C1q subcomponent subunit Atarget
DB00074BasiliximabComplement C1q subcomponent subunit Btarget
DB00074BasiliximabComplement C1q subcomponent subunit Ctarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00074BasiliximabComplement C1s subcomponenttarget
DB00074BasiliximabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00074BasiliximabInterleukin-2 receptor subunit betatarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00074BasiliximabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 epsilon chaintarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00075MuromonabComplement C1r subcomponenttarget
DB00075MuromonabComplement C1q subcomponent subunit Atarget
DB00075MuromonabComplement C1q subcomponent subunit Btarget
DB00075MuromonabComplement C1q subcomponent subunit Ctarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00075MuromonabComplement C1s subcomponenttarget
DB00075MuromonabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00075MuromonabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00075MuromonabT-cell surface glycoprotein CD3 delta chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 gamma chaintarget
DB00075MuromonabT-cell surface glycoprotein CD3 zeta chaintarget
DB00078Ibritumomab tiuxetanB-lymphocyte antigen CD20target
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00078Ibritumomab tiuxetanComplement C1r subcomponenttarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Atarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Btarget
DB00078Ibritumomab tiuxetanComplement C1q subcomponent subunit Ctarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00078Ibritumomab tiuxetanComplement C1s subcomponenttarget
DB00078Ibritumomab tiuxetanHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00078Ibritumomab tiuxetanLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00081TositumomabB-lymphocyte antigen CD20target
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00081TositumomabComplement C1r subcomponenttarget
DB00081TositumomabComplement C1q subcomponent subunit Atarget
DB00081TositumomabComplement C1q subcomponent subunit Btarget
DB00081TositumomabComplement C1q subcomponent subunit Ctarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00081TositumomabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00081TositumomabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00083Botulinum Toxin Type ASynaptosomal-associated protein 25target
DB00083Botulinum Toxin Type ARho-related GTP-binding protein RhoBtarget
DB00086StreptokinasePlasminogentarget
DB00086StreptokinaseProteinase-activated receptor 1target
DB00086StreptokinaseCytosolic phospholipase A2enzyme
DB00087AlemtuzumabCAMPATH-1 antigentarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00087AlemtuzumabComplement C1r subcomponenttarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Atarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Btarget
DB00087AlemtuzumabComplement C1q subcomponent subunit Ctarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00087AlemtuzumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00087AlemtuzumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00089Capromab pendetideGlutamate carboxypeptidase 2target
DB00092AlefaceptT-cell surface antigen CD2target
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00092AlefaceptComplement C1r subcomponenttarget
DB00092AlefaceptComplement C1q subcomponent subunit Atarget
DB00092AlefaceptComplement C1q subcomponent subunit Btarget
DB00092AlefaceptComplement C1q subcomponent subunit Ctarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00092AlefaceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00093FelypressinVasopressin V1a receptortarget
DB00095EfalizumabIntegrin alpha-Ltarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00095EfalizumabComplement C1r subcomponenttarget
DB00095EfalizumabComplement C1q subcomponent subunit Atarget
DB00095EfalizumabComplement C1q subcomponent subunit Btarget
DB00095EfalizumabComplement C1q subcomponent subunit Ctarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00095EfalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00095EfalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD1atarget
DB00098Antithymocyte immunoglobulin (rabbit)Major histocompatibility complex class I-related gene proteintarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Ltarget
DB00098Antithymocyte immunoglobulin (rabbit)T-lymphocyte activation antigen CD86target
DB00098Antithymocyte immunoglobulin (rabbit)Low affinity immunoglobulin gamma Fc region receptor II-btarget
DB00098Antithymocyte immunoglobulin (rabbit)T-cell surface glycoprotein CD4target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-1target
DB00098Antithymocyte immunoglobulin (rabbit)Integrin alpha-Vtarget
DB00098Antithymocyte immunoglobulin (rabbit)Integrin beta-3target
DB00099FilgrastimGranulocyte colony-stimulating factor receptortarget
DB00099FilgrastimNeutrophil elastasetarget
DB00102BecaplerminPlatelet-derived growth factor receptor betatarget
DB00102BecaplerminAlpha-2-macroglobulintarget
DB00102BecaplerminPlatelet-derived growth factor receptor alphatarget
DB00103Agalsidase betaGlobotriaosylceramidetarget
DB00105Interferon Alfa-2b, RecombinantInterferon alpha/beta receptor 2target
DB00105Interferon Alfa-2b, RecombinantInterferon alpha/beta receptor 1target
DB00105Interferon Alfa-2b, RecombinantCytochrome P450 1A2enzyme
DB00108NatalizumabIntegrin alpha-4target
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00108NatalizumabComplement C1r subcomponenttarget
DB00108NatalizumabComplement C1q subcomponent subunit Atarget
DB00108NatalizumabComplement C1q subcomponent subunit Btarget
DB00108NatalizumabComplement C1q subcomponent subunit Ctarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00108NatalizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00108NatalizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00108NatalizumabIntercellular adhesion molecule 1target
DB00109EnfuvirtideEnvelope glycoproteintarget
DB00109EnfuvirtideCytochrome P450 2C19enzyme
DB00109EnfuvirtideCytochrome P450 2E1enzyme
DB00110PalivizumabFusion glycoprotein F0target
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00110PalivizumabComplement C1r subcomponenttarget
DB00110PalivizumabComplement C1q subcomponent subunit Atarget
DB00110PalivizumabComplement C1q subcomponent subunit Btarget
DB00110PalivizumabComplement C1q subcomponent subunit Ctarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00110PalivizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00110PalivizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00111DaclizumabInterleukin-2 receptor subunit alphatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00111DaclizumabComplement C1r subcomponenttarget
DB00111DaclizumabComplement C1q subcomponent subunit Atarget
DB00111DaclizumabComplement C1q subcomponent subunit Btarget
DB00111DaclizumabComplement C1q subcomponent subunit Ctarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00111DaclizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00111DaclizumabInterleukin-2 receptor subunit betatarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00111DaclizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00112BevacizumabComplement C1r subcomponenttarget
DB00112BevacizumabComplement C1q subcomponent subunit Atarget
DB00112BevacizumabComplement C1q subcomponent subunit Btarget
DB00112BevacizumabComplement C1q subcomponent subunit Ctarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00112BevacizumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00112BevacizumabLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB00112BevacizumabVascular endothelial growth factor Atarget
DB00113Technetium Tc-99m arcitumomabCarcinoembryonic antigen-related cell adhesion molecule 1target
DB00155L-CitrullineNitric oxide synthase, endothelialtarget
DB00155L-CitrullineArgininosuccinate synthasetarget
DB00155L-CitrullineN(G),N(G)-dimethylarginine dimethylaminohydrolase 2target
DB00155L-CitrullineArgininosuccinate synthetase, isoform CRA_atarget
DB00155L-CitrullineN(G),N(G)-dimethylarginine dimethylaminohydrolase 1target
DB00155L-CitrullineOrnithine carbamoyltransferase, mitochondrialtarget
DB00155L-CitrullineNitric oxide synthase, braintarget
DB00155L-CitrullineNitric oxide synthase, inducibletarget
DB00155L-CitrullineProtein-arginine deiminase type-4target
DB00155L-CitrullineProtein-arginine deiminase type-6target
DB00155L-CitrullineProtein-arginine deiminase type-1target
DB00155L-CitrullineProtein-arginine deiminase type-3target
DB00155L-CitrullineProtein-arginine deiminase type-2target
DB00155L-CitrullineSolute carrier family 22 member 6transporter
DB00183PentagastrinGastrin/cholecystokinin type B receptortarget
DB00183PentagastrinCholinesteraseenzyme
DB00644GonadorelinGonadotropin-releasing hormone receptortarget
DB00644GonadorelinPutative gonadotropin-releasing hormone II receptortarget
DB00666NafarelinGonadotropin-releasing hormone receptortarget
DB00666NafarelinPutative gonadotropin-releasing hormone II receptortarget
DB00781Polymyxin B SulfateBacterial outer membranetarget
DB00803ColistinBacterial outer membranetarget
DB00855Aminolevulinic acidDelta-aminolevulinic acid dehydratasetarget
DB00855Aminolevulinic acidSolute carrier family 15 member 1transporter
DB00855Aminolevulinic acidSolute carrier family 15 member 2transporter
DB01111ColistimethateBacterial outer membranetarget
DB01229PaclitaxelApoptosis regulator Bcl-2target
DB01229PaclitaxelTubulin beta-1 chaintarget
DB01229PaclitaxelCytochrome P450 2C8enzyme
DB01229PaclitaxelCytochrome P450 3A4enzyme
DB01229PaclitaxelCytochrome P450 3A5enzyme
DB01229PaclitaxelCytochrome P450 3A7enzyme
DB01229PaclitaxelCytochrome P450 2C9enzyme
DB01229PaclitaxelBile salt export pumptransporter
DB01229PaclitaxelMultidrug resistance protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 1transporter
DB01229PaclitaxelMultidrug resistance-associated protein 7transporter
DB01229PaclitaxelCytochrome P450 19A1enzyme
DB01229PaclitaxelCytochrome P450 1B1enzyme
DB01229PaclitaxelSolute carrier organic anion transporter family member 1B3transporter
DB01229PaclitaxelNuclear receptor subfamily 1 group I member 2target
DB01229PaclitaxelMicrotubule-associated protein 4target
DB01229PaclitaxelMicrotubule-associated protein 2target
DB01229PaclitaxelMicrotubule-associated protein tautarget
DB01229PaclitaxelATP-binding cassette sub-family G member 2transporter
DB01229PaclitaxelCanalicular multispecific organic anion transporter 1transporter
DB01257EculizumabComplement C5target
DB01269PanitumumabEpidermal growth factor receptortarget
DB01270RanibizumabVascular endothelial growth factor Atarget
DB01277MecaserminInsulin-like growth factor 1 receptortarget
DB01277MecaserminInsulin-like growth factor-binding protein 3target
DB01277MecaserminInsulin receptortarget
DB01277MecaserminCation-independent mannose-6-phosphate receptortarget
DB01278PramlintideReceptor activity-modifying protein 1target
DB01278PramlintideReceptor activity-modifying protein 2target
DB01278PramlintideReceptor activity-modifying protein 3target
DB01278PramlintideCalcitonin receptortarget
DB01279GalsulfasePerilipin-3target
DB01279GalsulfaseDermatan sulfatetarget
DB01281AbataceptT-lymphocyte activation antigen CD80target
DB01281AbataceptT-lymphocyte activation antigen CD86target
DB01284TetracosactideAdrenocorticotropic hormone receptortarget
DB01285CorticotropinAdrenocorticotropic hormone receptortarget
DB01285CorticotropinCorticoliberintarget
DB01285Corticotropin3 beta-hydroxysteroid dehydrogenase/Delta 5-->4-isomerase type 2enzyme
DB01285Corticotropin25-hydroxyvitamin D-1 alpha hydroxylase, mitochondrialenzyme
DB01285Corticotropin1,25-dihydroxyvitamin D(3) 24-hydroxylase, mitochondrialenzyme
DB01309Insulin GlulisineInsulin receptortarget
DB01309Insulin GlulisineCytochrome P450 1A2enzyme
DB01373CalciumProtein S100-Btarget
DB01373CalciumCalpastatintarget
DB01373CalciumCartilage oligomeric matrix proteintarget
DB01373CalciumCalmodulintarget
DB01373CalciumSpectrin beta chain, non-erythrocytic 1target
DB01373CalciumVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB01373CalciumTroponin C, skeletal muscletarget
DB01373CalciumTroponin C, slow skeletal and cardiac musclestarget
DB01373CalciumCalcium-transporting ATPase type 2C member 1target
DB01373CalciumAmiloride-sensitive amine oxidase [copper-containing]target
DB01373CalciumProtein S100-A13target
DB01373CalciumAlkaline phosphatase, placental typetarget
DB01373CalciumProtein S100-A8target
DB01373CalciumProtein S100-A9target
DB01373CalciumProtein S100-A2target
DB01373CalciumCeruloplasmintarget
DB01373CalciumBone morphogenetic protein 4target
DB01373CalciumMatrix Gla proteintarget
DB01373CalciumProtocadherin-19target
DB01373CalciumProgrammed cell death protein 6target
DB01853Bacteriochlorophyll ABacteriochlorophyll a proteintarget
DB01853Bacteriochlorophyll ABacteriochlorophyll a proteintarget
DB02137Molybdenum CofactorAldehyde oxidoreductasetarget
DB02261Platelet Activating FactorGanglioside GM2 activatortarget
DB02261Platelet Activating FactorMultidrug resistance protein 1transporter
DB02261Platelet Activating FactorPlatelet-activating factor receptortarget
DB02638TerlipressinVasopressin V1a receptortarget
DB02638TerlipressinVasopressin V2 receptortarget
DB02638TerlipressinVasopressin V1b receptortarget
DB04894VapreotideSubstance-P receptortarget
DB04894VapreotideSomatostatin receptor type 2target
DB04894VapreotideSomatostatin receptor type 5target
DB04899NesiritideAtrial natriuretic peptide receptor 1target
DB04899NesiritideAtrial natriuretic peptide receptor 2target
DB04899NesiritideAtrial natriuretic peptide receptor 3target
DB04901GaliximabT-lymphocyte activation antigen CD80target
DB04925DesmoteplasePlasminogentarget
DB04931AfamelanotideMelanocyte-stimulating hormone receptortarget
DB04956AfelimomabTumor necrosis factortarget
DB04958EpratuzumabB-cell receptor CD22target
DB04964OregovomabMucin-16target
DB04985Tigapotide40S ribosomal protein SAtarget
DB04988IGN311Epidermal growth factor receptortarget
DB04988IGN311Receptor tyrosine-protein kinase erbB-2target
DB05029LancovutideCytosolic phospholipase A2enzyme
DB05032REV131Histamine H4 receptortarget
DB05084AbaloparatideParathyroid hormone/parathyroid hormone-related peptide receptortarget
DB05097LabetuzumabCarcinoembryonic antigentarget
DB05098LeptinLeptin receptortarget
DB05101MatuzumabEpidermal growth factor receptortarget
DB05111FontolizumabInterferon gammatarget
DB05115NN344Insulin receptortarget
DB05139CR002Platelet-derived growth factor Dtarget
DB05155CR665Kappa-type opioid receptortarget
DB05161ElafinNeutrophil elastasetarget
DB05161ElafinMyeloblastintarget
DB05161ElafinMyeloperoxidaseenzyme
DB05209SYM001Rhesus blood group D antigentarget
DB05258Natural alpha interferonInterferon alpha/beta receptor 1target
DB05259GlatiramerHLA class II histocompatibility antigen, DRB1-1 beta chaintarget
DB05276Hepatitis B Immune GlobulinHBsAgtarget
DB05299keyhole limpet hemocyaninInterleukin-2target
DB05305Cintredekin BesudotoxInterleukin-13target
DB05319oportuzumab monatoxEpithelial cell adhesion moleculetarget
DB05332RomiplostimThrombopoietin receptortarget
DB05394CorticorelinDopamine beta-hydroxylaseenzyme
DB05413TifuvirtidePlasma serine protease inhibitortarget
DB05446LJP 1082Beta-2-glycoprotein 1target
DB05459BriakinumabInterleukin-12 subunit betatarget
DB05459BriakinumabInterleukin-23 subunit alphatarget
DB05578RamucirumabVascular endothelial growth factor receptor 2target
DB05595FarletuzumabFolate receptor alphatarget
DB05679UstekinumabInterleukin-12 subunit betatarget
DB05679UstekinumabInterleukin-23target
DB05773Trastuzumab emtansineReceptor tyrosine-protein kinase erbB-2target
DB05773Trastuzumab emtansineMultidrug resistance protein 1transporter
DB05773Trastuzumab emtansineCytochrome P450 3A4enzyme
DB05773Trastuzumab emtansineCytochrome P450 3A5enzyme
DB05777Thrombomodulin AlfaCoagulation factor Vtarget
DB05777Thrombomodulin AlfaProthrombintarget
DB05793PRO-542Free fatty acid receptor 4target
DB05797TNX-901High affinity immunoglobulin epsilon receptor subunit alphatarget
DB05875substance PCytochrome P450 19A1enzyme
DB05875substance PCholinesteraseenzyme
DB05875substance PProstaglandin G/H synthase 2enzyme
DB05889Inotuzumab ozogamicinMultidrug resistance protein 1transporter
DB05889Inotuzumab ozogamicinB-cell receptor CD22target
DB05892RI 624Beta-nerve growth factortarget
DB05915MYO-029Growth/differentiation factor 8target
DB05931PegdinetanibVascular endothelial growth factor receptor 2target
DB05996Glembatumumab vedotinTransmembrane glycoprotein NMBtarget
DB06043OlaratumabPlatelet-derived growth factor receptor alphatarget
DB06081Caplacizumabvon Willebrand factortarget
DB06101IMC-1C11Vascular endothelial growth factor receptor 1target
DB06101IMC-1C11Vascular endothelial growth factor receptor 2target
DB06101IMC-1C11Vascular endothelial growth factor receptor 3target
DB06116EldelumabC-X-C motif chemokine 10target
DB06138IRL-1620Endothelin B receptortarget
DB06162LumiliximabLow affinity immunoglobulin epsilon Fc receptortarget
DB06168CanakinumabInterleukin-1 betatarget
DB06186IpilimumabCytotoxic T-lymphocyte protein 4target
DB06196IcatibantB2 bradykinin receptortarget
DB06196IcatibantAminopeptidase Ntarget
DB06241ClenoliximabT-cell surface glycoprotein CD4target
DB06245LanoteplaseUrokinase plasminogen activator surface receptortarget
DB06245LanoteplaseFibrinogen alpha chaintarget
DB06245LanoteplaseKallikrein-1target
DB06245LanoteplaseLaminin subunit alpha-5target
DB06245LanoteplaseCoagulation factor Xtarget
DB06245LanoteplaseFibronectintarget
DB06245LanoteplasePlasminogen activator inhibitor 2target
DB06245LanoteplaseTetranectintarget
DB06245LanoteplaseKeratin, type II cytoskeletal 8target
DB06245LanoteplaseAnnexin A2target
DB06245LanoteplaseLaminin subunit beta-1target
DB06245LanoteplaseLaminin subunit gamma-1target
DB06245LanoteplaseLaminin subunit alpha-1target
DB06245LanoteplaseCalreticulintarget
DB06245LanoteplaseCalnexintarget
DB06245LanoteplaseProlow-density lipoprotein receptor-related protein 1target
DB06245LanoteplaseLaminin subunit alpha-3target
DB06273TocilizumabInterleukin-6 receptor subunit alphatarget
DB06317ElotuzumabSLAM family member 7target
DB06342Coltuximab ravtansineB-lymphocyte antigen CD19target
DB06360LucatumumabTumor necrosis factor receptor superfamily member 5target
DB06366PertuzumabReceptor tyrosine-protein kinase erbB-2target
DB06371SiplizumabT-cell surface antigen CD2target
DB06372RilonaceptInterleukin-1 betatarget
DB06372RilonaceptInterleukin-1 alphatarget
DB06372RilonaceptInterleukin-1 receptor antagonist proteintarget
DB06404Human C1-esterase inhibitorComplement C1r subcomponenttarget
DB06404Human C1-esterase inhibitorComplement C1s subcomponenttarget
DB06404Human C1-esterase inhibitorPlasma kallikreintarget
DB06404Human C1-esterase inhibitorCoagulation factor XIItarget
DB06404Human C1-esterase inhibitorProthrombintarget
DB06404Human C1-esterase inhibitorCoagulation factor XItarget
DB06404Human C1-esterase inhibitorTissue-type plasminogen activatortarget
DB06495OnerceptTumor necrosis factortarget
DB06534ThrombopoietinThrombopoietin receptortarget
DB06549LabradimilB2 bradykinin receptortarget
DB06550BivatuzumabCD44 antigentarget
DB06599LexatumumabTumor necrosis factor receptor superfamily member 10Btarget
DB06602ReslizumabInterleukin-5target
DB06607CatumaxomabEpithelial cell adhesion moleculetarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB06607CatumaxomabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB06607CatumaxomabT-cell surface glycoprotein CD3 epsilon chaintarget
DB06607CatumaxomabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB06612MepolizumabInterleukin-5target
DB06643DenosumabTumor necrosis factor ligand superfamily member 11target
DB06650OfatumumabB-lymphocyte antigen CD20target
DB06655LiraglutideGlucagon-like peptide 1 receptortarget
DB06655LiraglutideDipeptidyl peptidase 4enzyme
DB06655LiraglutideNeprilysinenzyme
DB06663PasireotideSomatostatin receptor type 1target
DB06663PasireotideSomatostatin receptor type 2target
DB06663PasireotideSomatostatin receptor type 3target
DB06663PasireotideSomatostatin receptor type 5target
DB06674GolimumabTumor necrosis factortarget
DB06681BelataceptT-lymphocyte activation antigen CD86target
DB06681BelataceptT-lymphocyte activation antigen CD80target
DB06692AprotininTrypsin-1target
DB06692AprotininChymotrypsinogen Btarget
DB06692AprotininPlasminogentarget
DB06692AprotininKallikrein-1target
DB06719BuserelinLutropin-choriogonadotropic hormone receptortarget
DB06719BuserelinGonadotropin-releasing hormone receptortarget
DB06719BuserelinCytochrome P450 19A1enzyme
DB06785GanirelixGonadotropin-releasing hormone receptortarget
DB06788HistrelinGonadotropin-releasing hormone receptortarget
DB06791LanreotideSomatostatin receptor type 2target
DB06791LanreotideSomatostatin receptor type 5target
DB06825TriptorelinGonadotropin-releasing hormone receptortarget
DB08856DADLESolute carrier organic anion transporter family member 1B1transporter
DB08861DPDPESolute carrier organic anion transporter family member 1B3transporter
DB08869TesamorelinGrowth hormone-releasing hormone receptortarget
DB08870Brentuximab vedotinTumor necrosis factor receptor superfamily member 8target
DB08870Brentuximab vedotinCytochrome P450 3A4enzyme
DB08870Brentuximab vedotinATP-binding cassette sub-family B member 5transporter
DB08879BelimumabTumor necrosis factor ligand superfamily member 13Btarget
DB08885AfliberceptVascular endothelial growth factor Atarget
DB08885AfliberceptPlacenta growth factortarget
DB08885AfliberceptVascular endothelial growth factor Btarget
DB08900TeduglutideGlucagon-like peptide 2 receptortarget
DB08902RaxibacumabProtective antigentarget
DB08904Certolizumab pegolTumor necrosis factortarget
DB08935ObinutuzumabB-lymphocyte antigen CD20target
DB09029SecukinumabInterleukin-17Atarget
DB09033VedolizumabIntegrin alpha-4target
DB09033VedolizumabIntegrin beta-7target
DB09035NivolumabProgrammed cell death protein 1target
DB09036SiltuximabInterleukin-6target
DB09037PembrolizumabProgrammed cell death protein 1target
DB09043AlbiglutideGlucagon-like peptide 1 receptortarget
DB09045DulaglutideGlucagon-like peptide 1 receptortarget
DB09046MetreleptinLeptin receptortarget
DB09052BlinatumomabB-lymphocyte antigen CD19target
DB09052BlinatumomabT-cell surface glycoprotein CD3 delta chaintarget
DB09067Corticorelin ovine triflutateCorticotropin-releasing factor receptor 1target
DB09077DinutuximabGanglioside GD2target
DB09099SomatostatinSomatostatin receptor type 1target
DB09099SomatostatinSomatostatin receptor type 2target
DB09099SomatostatinSomatostatin receptor type 3target
DB09099SomatostatinSomatostatin receptor type 4target
DB09099SomatostatinSomatostatin receptor type 5target
DB09099SomatostatinMultidrug resistance protein 1transporter
DB09103AncestimMast/stem cell growth factor receptor Kittarget
DB09105Asfotase AlfaSphingosine 1-phosphate receptor 1target
DB09105Asfotase AlfaPyrophosphatetarget
DB09107Methoxy polyethylene glycol-epoetin betaErythropoietin receptortarget
DB09109Turoctocog alfaCoagulation factor IXtarget
DB09109Turoctocog alfaCoagulation factor Xtarget
DB09109Turoctocog alfaProthrombintarget
DB09126Chorionic Gonadotropin (Human)Lutropin-choriogonadotropic hormone receptortarget
DB09221PolaprezincTumor necrosis factortarget
DB09221PolaprezincInterleukin-6target
DB09221PolaprezincInterleukin-3target
DB09221PolaprezincSuperoxide dismutase [Cu-Zn]enzyme
DB09221PolaprezincHeme oxygenase 1enzyme
DB09221PolaprezincSuperoxide dismutase [Mn], mitochondrialenzyme
DB09221PolaprezincGlutathione S-transferase theta-1enzyme
DB09221PolaprezincGlutathione peroxidase 1enzyme
DB09221PolaprezincPeroxiredoxin-1enzyme
DB09221PolaprezincPeroxiredoxin-5, mitochondrialenzyme
DB09221PolaprezincVascular endothelial growth factor receptor 1target
DB09221PolaprezincBeta-nerve growth factortarget
DB09221PolaprezincPlatelet-derived growth factor receptor betatarget
DB09221PolaprezincHeat shock protein HSP 90-alphatarget
DB09221PolaprezincHeat shock protein HSP 90-betatarget
DB09264IdarucizumabDabigatran etexilatetarget
DB09302AlirocumabProprotein convertase subtilisin/kexin type 9target
DB09303EvolocumabProprotein convertase subtilisin/kexin type 9enzyme
DB09331DaratumumabADP-ribosyl cyclase 1target
DB09421ProtirelinThyrotropin Releasing Hormone Receptortarget
DB09559NecitumumabEpidermal growth factor receptortarget
DB11095DesirudinCarboxypeptidase A1enzyme
DB11300ThrombinProteinase-activated receptor 1target
DB11300ThrombinProteinase-activated receptor 4target
DB11300ThrombinCoagulation factor XItarget
DB11300ThrombinCoagulation factor XIII A chaintarget
DB11300ThrombinCoagulation factor XIII B chaintarget
DB11300ThrombinFibrinogen alpha chaintarget
DB11300ThrombinFibrinogen beta chaintarget
DB11300ThrombinFibrinogen gamma chaintarget
DB11300ThrombinCoagulation factor Vtarget
DB11300ThrombinCoagulation factor VIIItarget
DB11311ProthrombinFibrinogen alpha chaintarget
DB11311ProthrombinFibrinogen beta chaintarget
DB11311ProthrombinCoagulation factor XIII A chaintarget
DB11311ProthrombinCarboxypeptidase B2target
DB11311ProthrombinCoagulation factor Xenzyme
DB11569IxekizumabInterleukin-17Atarget
DB11595AtezolizumabProgrammed cell death 1 ligand 1target
DB11598Antithrombin III humanAntithrombin-IIItarget
DB11639Dibotermin alfaBone morphogenetic protein receptor type-1Atarget
DB11639Dibotermin alfaBone morphogenetic protein receptor type-2target
DB11714DurvalumabProgrammed cell death 1 ligand 1target
DB11714DurvalumabT-lymphocyte activation antigen CD80target
DB11767SarilumabAlanine aminotransferase 1enzyme
DB11767SarilumabAlanine aminotransferase 2enzyme
DB11767SarilumabAspartate aminotransferaseenzyme
DB11767SarilumabCytochrome P450 3A4enzyme
DB11767SarilumabInterleukin-6 receptor subunit alphatarget
DB11767SarilumabHigh affinity immunoglobulin gamma Fc receptor Itarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB11767SarilumabLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB11834GuselkumabInterleukin-23 subunit alphatarget
DB11842Angiotensin IIType-1 angiotensin II receptortarget
DB11945AvelumabProgrammed cell death 1 ligand 1target
DB11988OcrelizumabB-lymphocyte antigen CD20target
DB12118SotaterceptActivin receptor type-2Atarget
DB12119GevokizumabInterleukin-1 betatarget
DB12159DupilumabInterleukin-4 receptor subunit alphatarget
DB12250CixutumumabInsulin-like growth factor 1 receptortarget
DB12589DacetuzumabTumor necrosis factor receptor superfamily member 5target
DB12698IbalizumabT-cell surface glycoprotein CD4target
DB12698IbalizumabC-C chemokine receptor type 5target
DB12698IbalizumabC-X-C chemokine receptor type 4target
DB12845AmatuximabMesothelintarget
DB13133Von Willebrand Factor HumanCoagulation factor VIIItarget
DB13133Von Willebrand Factor HumanCollagen alpha-1(I) chaintarget
DB13133Von Willebrand Factor HumanA disintegrin and metalloproteinase with thrombospondin motifs 13enzyme
DB13144LenograstimGranulocyte colony-stimulating factor receptortarget
DB13149Protein S humanCoagulation factor Vtarget
DB13149Protein S humanCoagulation factor Xtarget
DB13149Protein S humanVitamin K-dependent protein Ctarget
DB13150Coagulation factor VII humanTissue factortarget
DB13150Coagulation factor VII humanCoagulation factor Xtarget
DB13150Coagulation factor VII humanCoagulation factor IXtarget
DB13192Antihemophilic factor humanCoagulation factor IXtarget
DB13192Antihemophilic factor humanCoagulation factor Xtarget
DB13192Antihemophilic factor humanVitamin K-dependent protein Cenzyme
DB13200LipegfilgrastimGranulocyte colony-stimulating factor receptortarget
DB13257Ferrous sulfateSerotransferrintransporter
DB13257Ferrous sulfateFerritin light chaintransporter
DB13257Ferrous sulfateFerritin heavy chaintransporter
DB13257Ferrous sulfateDivalent metal ion transporter 1transporter
DB13257Ferrous sulfateIron binding protein FbpAtransporter
DB13257Ferrous sulfateNADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrialenzyme
DB13257Ferrous sulfateSuccinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrialenzyme
DB13257Ferrous sulfateXanthine dehydrogenase/oxidaseenzyme
DB13257Ferrous sulfateAconitate hydratase, mitochondrialenzyme
DB13257Ferrous sulfateCytochrome P450 4A11enzyme
DB13257Ferrous sulfateSulfite oxidase, mitochondrialenzyme
DB13257Ferrous sulfateMyeloperoxidaseenzyme
DB13257Ferrous sulfateCatalaseenzyme
DB13257Ferrous sulfateNitric oxide synthase, inducibleenzyme
DB13257Ferrous sulfateProstaglandin G/H synthase 1enzyme
DB13257Ferrous sulfateProstaglandin G/H synthase 2enzyme
DB13257Ferrous sulfateTryptophan 5-hydroxylase 1enzyme
DB13257Ferrous sulfateProlyl 4-hydroxylase subunit alpha-1enzyme
DB13257Ferrous sulfateRibonucleoside-diphosphate reductase large subunitenzyme
DB13257Ferrous sulfatePterin-4-alpha-carbinolamine dehydrataseenzyme
DB13257Ferrous sulfateTrimethyllysine dioxygenase, mitochondrialenzyme
DB13257Ferrous sulfateCeruloplasminenzyme
DB13257Ferrous sulfateFree radicalstarget
DB13923EmicizumabCoagulation factor IXtarget
DB13923EmicizumabCoagulation factor Xtarget
DB13928SemaglutideSerum albumincarrier
DB13928SemaglutideDipeptidyl peptidase 4enzyme
DB13928SemaglutideNeprilysinenzyme
DB13928SemaglutideGlucagon-like peptide 1 receptortarget
DB13928SemaglutideSolute carrier organic anion transporter family member 1B1transporter
DB13928SemaglutideSolute carrier organic anion transporter family member 1B3transporter
DB13928SemaglutideLipoprotein lipaseenzyme
DB13928SemaglutideAlpha-amylase 1enzyme
DB13933Nonacog beta pegolCoagulation factor VIItarget
DB13933Nonacog beta pegolCoagulation factor VIIItarget
DB13933Nonacog beta pegolCoagulation factor Xtarget
DB13979BesilesomabCarcinoembryonic antigentarget
DB13999Moroctocog alfaCoagulation factor Xtarget
DB13999Moroctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB13999Moroctocog alfaCoagulation factor IXtarget
DB13999Moroctocog alfaAsialoglycoprotein receptor 2target
DB13999Moroctocog alfa78 kDa glucose-regulated proteintarget
DB13999Moroctocog alfaCalreticulintarget
DB13999Moroctocog alfaCalnexintarget
DB13999Moroctocog alfaProtein ERGIC-53target
DB13999Moroctocog alfaProlow-density lipoprotein receptor-related protein 1target
DB13999Moroctocog alfaMultiple coagulation factor deficiency protein 2target
DB13999Moroctocog alfavon Willebrand factortarget
DB13999Moroctocog alfaProthrombinenzyme
DB13999Moroctocog alfaVitamin K-dependent protein Cenzyme
DB14004TildrakizumabInterleukin-23target
DB14004TildrakizumabCytochrome P450 4A11enzyme
DB14039ErenumabCalcitonin gene-related peptide type 1 receptortarget
DB14041FremanezumabCalcitonin gene-related peptide 1target
DB14041FremanezumabCalcitonin gene-related peptide 2target